Sarepta Therapeutics annual operating income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Operating Income Growth & History (SRPT)
Sarepta Therapeutics's operating income was −$699.8M for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$699.8M | −$917.9M | — |
| 2024 | 2024-12-31 | $218.1M | $485.9M | — |
| 2023 | 2023-12-31 | −$267.8M | $268.4M | — |
| 2022 | 2022-12-31 | −$536.2M | −$76.5M | — |
| 2021 | 2021-12-31 | −$459.7M | $104.5M | — |
| 2020 | 2020-12-31 | −$564.2M | $141.4M | — |
| 2019 | 2019-12-31 | −$705.6M | −$361.9M | — |
| 2018 | 2018-12-31 | −$343.6M | −$172.0M | — |
| 2017 | 2017-12-31 | −$171.6M | $95.1M | — |
| 2016 | 2016-12-31 | −$266.7M | −$46.5M | — |
| 2015 | 2015-12-31 | −$220.2M | −$86.4M | — |
| 2014 | 2014-12-31 | −$133.8M | −$43.5M | — |
| 2013 | 2013-12-31 | −$90.3M | −$60.6M | — |
| 2012 | 2012-12-31 | −$29.7M | $6.2M | — |
| 2011 | 2011-12-31 | −$35.9M | −$15.0M | — |
| 2010 | 2010-12-31 | −$20.9M | −$5.4M | — |
| 2009 | 2009-12-31 | −$15.5M | — | — |
Sarepta Therapeutics quarterly operating income
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $13.3M | −$102.3M | −88.50% |
| Q1 2026 | 2026-03-31 | $358.4M | $658.8M | — |
| Q4 2025 | 2025-12-31 | −$411.6M | −$573.3M | — |
| Q3 2025 | 2025-09-30 | −$103.4M | −$125.6M | — |
| Q2 2025 | 2025-06-30 | $115.6M | $116.3M | — |
| Q1 2025 | 2025-03-31 | −$300.4M | −$335.3M | — |
| Q4 2024 | 2024-12-31 | $161.7M | $137.1M | +556.57% |
| Q3 2024 | 2024-09-30 | $22.2M | $43.0M | — |
| Q2 2024 | 2024-06-30 | −$701,000 | $132.8M | — |
| Q1 2024 | 2024-03-31 | $34.9M | $173.0M | — |
| Q4 2023 | 2023-12-31 | $24.6M | $131.5M | — |
| Q3 2023 | 2023-09-30 | −$20.8M | $110.5M | — |
| Q2 2023 | 2023-06-30 | −$133.5M | $77.6M | — |
| Q1 2023 | 2023-03-31 | −$138.1M | −$51.2M | — |
| Q4 2022 | 2022-12-31 | −$106.8M | −$1.0M | — |
| Q3 2022 | 2022-09-30 | −$131.4M | −$96.9M | — |
| Q2 2022 | 2022-06-30 | −$211.1M | −$43.6M | — |
| Q1 2022 | 2022-03-31 | −$86.9M | $65.0M | — |
| Q4 2021 | 2021-12-31 | −$105.8M | $64.9M | — |
| Q3 2021 | 2021-09-30 | −$34.5M | $102.6M | — |
| Q2 2021 | 2021-06-30 | −$167.6M | −$29.2M | — |
| Q1 2021 | 2021-03-31 | −$151.9M | −$33.8M | — |
| Q4 2020 | 2020-12-31 | −$170.7M | $59.5M | — |
| Q3 2020 | 2020-09-30 | −$137.1M | −$13.5M | — |
| Q2 2020 | 2020-06-30 | −$138.4M | $137.0M | — |
| Q1 2020 | 2020-03-31 | −$118.0M | −$41.6M | — |
| Q4 2019 | 2019-12-31 | −$230.2M | −$90.9M | — |
| Q3 2019 | 2019-09-30 | −$123.6M | −$53.5M | — |
| Q2 2019 | 2019-06-30 | −$275.4M | −$171.9M | — |
| Q1 2019 | 2019-03-31 | −$76.4M | −$45.6M | — |
| Q4 2018 | 2018-12-31 | −$139.4M | −$116.2M | — |
| Q3 2018 | 2018-09-30 | −$70.1M | −$24.2M | — |
| Q2 2018 | 2018-06-30 | −$103.4M | −$40.1M | — |
| Q1 2018 | 2018-03-31 | −$30.7M | $8.5M | — |
| Q4 2017 | 2017-12-31 | −$23.1M | $65.2M | — |
| Q3 2017 | 2017-09-30 | −$45.9M | $10.6M | — |
| Q2 2017 | 2017-06-30 | −$63.3M | −$1.2M | — |
| Q1 2017 | 2017-03-31 | −$39.2M | $20.5M | — |
| Q4 2016 | 2016-12-31 | −$88.4M | −$23.9M | — |
| Q3 2016 | 2016-09-30 | −$56.5M | −$4.8M | — |
| Q2 2016 | 2016-06-30 | −$62.1M | −$20.0M | — |
| Q1 2016 | 2016-03-31 | −$59.7M | $2.2M | — |
| Q4 2015 | 2015-12-31 | −$64.5M | −$19.7M | — |
| Q3 2015 | 2015-09-30 | −$51.8M | −$18.1M | — |
| Q2 2015 | 2015-06-30 | −$42.1M | −$11.8M | — |
| Q1 2015 | 2015-03-31 | −$61.9M | −$36.7M | — |
| Q4 2014 | 2014-12-31 | −$44.7M | −$11.9M | — |
| Q3 2014 | 2014-09-30 | −$33.7M | −$8.7M | — |
| Q2 2014 | 2014-06-30 | −$30.3M | −$13.2M | — |
| Q1 2014 | 2014-03-31 | −$25.1M | −$9.7M | — |
| Q4 2013 | 2013-12-31 | −$32.8M | −$22.5M | — |
| Q3 2013 | 2013-09-30 | −$24.9M | −$18.0M | — |
| Q2 2013 | 2013-06-30 | −$17.1M | −$11.5M | — |
| Q1 2013 | 2013-03-31 | −$15.4M | −$8.5M | — |
| Q4 2012 | 2012-12-31 | −$10.4M | −$1.4M | — |
| Q3 2012 | 2012-09-30 | −$6.9M | $4.4M | — |
| Q2 2012 | 2012-06-30 | −$5.6M | $4.6M | — |
| Q1 2012 | 2012-03-31 | −$6.9M | −$1.3M | — |
| Q4 2011 | 2011-12-31 | −$9.0M | — | — |
| Q3 2011 | 2011-09-30 | −$11.3M | −$7.5M | — |
| Q2 2011 | 2011-06-30 | −$10.1M | −$2.5M | — |
| Q1 2011 | 2011-03-31 | −$5.5M | — | — |
| Q3 2010 | 2010-09-30 | −$3.8M | — | — |
| Q2 2010 | 2010-06-30 | −$7.7M | — | — |
Sarepta Therapeutics operating income trends
Over the last five fiscal years, Sarepta Therapeutics's operating income decreased from −$564.2M to −$699.8M, a change of −$135.6M. The latest reported quarter, Q2 2026, shows $13.3M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...